{"nctId":"NCT02157948","briefTitle":"A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis","startDateStruct":{"date":"2014-05"},"conditions":["Postmenopausal Osteoporosis"],"count":394,"armGroups":[{"label":"Denosumab CP2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Denosumab (CP2)"]},{"label":"Denosumab CP4","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab (CP4)"]}],"interventions":[{"name":"Denosumab (CP2)","otherNames":["XGEVAÂ®"]},{"name":"Denosumab (CP4)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has provided informed consent prior to any study-specific activities/procedures\n* Ambulatory postmenopausal women.\n* Age 55 years or older\n* Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck.\n\nExclusion Criteria:\n\n* Administration of osteoporosis treatments or bone active treatments within specific timeframes\n* Vitamin D deficiency\n* Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled)\n* Contraindications to denosumab therapy (e.g., hypocalcemia)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Lumbar Spine BMD","description":"Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","spread":"3.44"},{"groupId":"OG001","value":"5.73","spread":"3.08"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.39","spread":null},{"groupId":"OG001","value":"-88.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.46","spread":null},{"groupId":"OG001","value":"-79.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.34","spread":null},{"groupId":"OG001","value":"-75.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.59","spread":null},{"groupId":"OG001","value":"-29.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.63","spread":null},{"groupId":"OG001","value":"-77.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.44","spread":null},{"groupId":"OG001","value":"-72.08","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":196},"commonTop":["Nasopharyngitis","Arthralgia"]}}}